Trials / Terminated
TerminatedNCT06685068
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Genmab · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GEN1286 | Specified dose on specified days. |
Timeline
- Start date
- 2024-11-13
- Primary completion
- 2026-03-12
- Completion
- 2026-03-12
- First posted
- 2024-11-12
- Last updated
- 2026-04-14
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06685068. Inclusion in this directory is not an endorsement.